<DOC>
	<DOCNO>NCT00555087</DOCNO>
	<brief_summary>The main objective study evaluate response erectile dysfunction hypogonadotrophic male Testosterone undecanoate i.m . per IIEF question GAQ ( Global Evaluation Questionnaire ) 42 week treatment . Secondary Study Objectives - To monitor adverse event change hemoglobin serum chemistry : PSA , lipid profile , renal-hepatic profile glycemia , control mean rectal digital examination . - To Determinate physiologic reconstitution patient treatment mean total free testosterone dosage .</brief_summary>
	<brief_title>Treatment Erectile Dysfunction Hypogonadal Men With Testosterone Undecanoate</brief_title>
	<detailed_description>The importance testosterone desire , interest sexual motivation well know , effect erectile function continue provoke controversy . Data obtain animal experimental surgical castration , explain condition cause veno-occlusive dysfunction therefore erectile dysfunction . In model animal flebogenous erectile dysfunction , intracavernous vascular endothelial growth factor ( VEGF ) , together testosterone , reestablishes balance muscle conjunctive tissue , hypertrophy hyperplasia endothelial cell regularize diameter dorsal nervous cell , thus prevent veno-occlusive dysfunction . Castration also induce apopthosis erectile tissue penis ; treatment testosterone provoke new DNA synthesis . There certain indicator treatment testosterone could help patient erectile dysfunction low testosterone base line amount . Likewise , androgen could control expression activity type 5 phosphodiesterase ( PDE-5 ) cavernous body penis . Pharmacological treatment PDE-5 inhibitor , administer orally fail certain case erectile dysfunction , even hypogonadal male . Some study show combination testosterone PDE-5 inhibitor help recovery sexual function patient ; therefore , give possibility combine pharmacological treatment testosterone erectile dysfunction .</detailed_description>
	<mesh_term>Erectile Dysfunction</mesh_term>
	<mesh_term>Testosterone undecanoate</mesh_term>
	<mesh_term>Testosterone</mesh_term>
	<mesh_term>Testosterone enanthate</mesh_term>
	<mesh_term>Testosterone 17 beta-cypionate</mesh_term>
	<mesh_term>Methyltestosterone</mesh_term>
	<criteria>Patients older 18 year old young 70 year . To diagnosis erectile dysfunction IIEF . Qualification less 46 point and/or GAQ Answer `` NO '' . Patients Inform consent letter sign . Patients without therapy type testosterone , gonadotrophines and/or PDE5 previous 4 week inclusion study . Diagnosis hypogonadism accord criterion : Testosterone dosage low 12 nmol/L Free testosterone shall 180 pmol/L 52 pg/mL People le 18 year old old 70 year . Patients history know suspected sleep apnea . Patients participate study protocol Known suspect active systemic infection . Patients HIV + and/ know HTLV+ . Patients hyperprolactinemia Patients know suspected coagulopathies Patients Klinefelter Known suspect psychiatric illness . Patients receive prior therapy kind testosterone last 4 month PDE5 inhibitor last month . Patients contraindication use PDE5 inhibitor Patients diagnosis erectile dysfunction total and/ free testosterone level within physiological range . Patients APE â‰¥ 2.5 ng/ml young 60 year , &gt; de 3 ng/ml old 60 year . Abnormal prostate finding digital rectal examination ( say , irregularity , hard consistency examine ) . Concomitant malignant disease history prostate cancer</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>November 2007</verification_date>
	<keyword>Erectile dysfunction</keyword>
	<keyword>Hypogonadotrophic male</keyword>
</DOC>